. Author manuscript; available in PMC: 2010 Jul 1.

Published in final edited form as: J Am Acad Dermatol. 2009 May 21;61(1):66–72. doi: 10.1016/j.jaad.2009.02.011

Table 1.

Statin Use, Non-statin antilipemics use and subsequent BCC risk in full cohort and sub-cohort (statin eligible)

Analysis Model	HR unadjusted	95% CI	p-value	HR Adjusted^*	95% CI	p-value

Full Cohort: Statin use
Eve/Never
Unexposed^**(n=10588)	1.000	Referent		1.000	Referent
Exposed (n=1535)	1.156	(1.048,1.276)	0.0038	1.016	(0.920,1.122)	0.752

Cumulative^◊ (n=12,123)	1.062	(1.028,1.097)	0.0003	1.023	(0.990, 1.057)	0.180

Categorical cumulative
Unexposed^**(n=10588)	1.000	Referent		1.000	Referent
Short-term (n=677)	1.110	(0.985, 1.250)	0.0861	0.981	(0.871, 1.106)	0.7571
Moderate (n=605)	1.200	(1.013, 1.420)	0.0347	1.047	(0.884, 1.241)	0.5923
Long-term (n=253)	1.546	(1.108, 2.157)	0.0104	1.299	(0.930, 1.814)	0.1246
		*Trend*	*0.0006*		*Trend*	*0.1958*

Statin eligible Sub-Cohort: Statin use
Ever/Never
Unexposed^**(n=1266)	1.000	Referent		1.000	Referent
Exposed (n=476)	1.102	(0.925, 1.312)	0.2768	1.067	(0.896, 1.270)	0.4685

Cumulative^◊ (n= 1742)	1.055	(0.997, 1.117)	0.0642	1.048	(0.990, 1.110)	0.1031

Categorical cumulative
Unexposed^** (n=1266)
Short-term (n=198)	1.000	Referent		1.000	Referent
Moderate (n=189)	1.040	(0.847, 1.276)	0.7089	1.002	(0.816, 1.229)	0.9863
Long-term (n=89)	1.216	(0.918, 1.610)	0.1721	1.192	(0.901, 1.577)	0.2193
	1.380	(0.809, 2.354)	0.2373	1.329	(0.779, 2.266)	0.2967
		*Trend*	*0.0992*		*Trend*	*0.1522*

Full Cohort: Non-statin antilipemics use
Ever/Never
Unexposed^**(n=11812)	1.000	Referent		1.00	Referent
Exposed (n=120)	1.189	(0.825, 1.714)	0.352	1.098	(0.762, 1.582)	0.6165

Adjusted for age, gender and average medical visits per year of follow-up

^**

No statin prescriptions with at least one refill at KPNC pharmacies during follow-up

^◊

Risk per one additional year cumulative statin exposure